Rallybio Corp

NASDAQ RLYB

Data sourced from

and

Download Data

Rallybio Corp Operating Cash Flow to Debt Ratio 5 year CAGR for the quarter ending September 20, 2024

Rallybio Corp Operating Cash Flow to Debt Ratio 5 year CAGR is NA for the quarter ending September 20, 2024. The operating cash flow to debt ratio measures the ability of a company's operating cash flow to cover its total debt obligations. It is calculated by dividing the operating cash flow by the total debt. This ratio provides insights into the company's ability to generate cash flow from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating cash flow relative to the level of debt, suggesting potential financial strength and debt servicing capability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

NASDAQ: RLYB

Rallybio Corp

CEO	Dr. Martin W. MacKay Ph.D.
IPO Date	July 29, 2021
Location	United States
Headquarters	234 Church Street, New Haven, CT, United States, 06510
Employees	30
Sector	Healthcare
Industry	Biotechnology

Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Key trends